PEPG Investors Encouraged to Participate in PepGen Inc. Class Action Lawsuit

Investors Take Note: Join the PepGen Inc. Class Action

The Rosen Law Firm, an esteemed global investor rights firm, is calling the attention of individuals who purchased securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024, and March 3, 2025. If you're among those affected, you could have the chance to recover damages without incurring any costs upfront, thanks to a contingency fee arrangement. Here’s what you need to know about this pivotal situation.

Key Dates and What You Need to Do

The critical deadline to act is August 8, 2025—the date by which you must apply to be named as the lead plaintiff in the case. Should you decide to participate in the class action, you can do so by visiting Rosen Legal’s submission page or contacting Phillip Kim, Esq. directly at 866-767-3653. An email can also be sent to [email protected] for more information.

It’s important to act swiftly: while a lawsuit has already been filed, your role as a lead plaintiff, representing fellow class members, must be formalized in court before the August deadline.

Why Choose the Rosen Law Firm?

Investors are encouraged to select an attorney with proven credentials and a strong track record in leading similar lawsuits. Rosen Law Firm has demonstrated success within this arena, having achieved particularly noteworthy settlements; for instance, they attained the largest securities class action settlement against a Chinese company at a point in time.

In terms of recognition, the firm has consistently ranked at the top for securities class action settlements since 2013, recovering hundreds of millions of dollars for investors. In 2019 alone, they secured over $438 million, illustrating their capability and commitment to protecting investor rights.

The Allegations Against PepGen Inc.

The lawsuit claims that throughout the specified Class Period, PepGen and its executives made a series of false and misleading statements. They allegedly downplayed the effectiveness and safety of their drug PGN-EDO51, implying that it was more promising than evidence suggested. The concerns were compounded by the CONNECT2 study, which the defendants reportedly knew was inadequate for approval by the U.S. Food and Drug Administration (FDA).

As the truth about the safety and efficacy of the drug became public, investors faced significant losses. These allegations highlight a troubling lack of transparency and integrity in PepGen's communications with its investors.

What to Consider Going Forward

It's critical to understand that, at this stage, no class has been certified. Thus, if you choose not to act, you are still able to remain an absent member of the class without taking further steps. The opportunity to participate in any future recovery will depend primarily on your engagement in this process. The more proactive you are, the better positioned you will be to recoup losses.

Updates and further details on the proceeding can be followed through the Rosen Law Firm's social media platforms, including LinkedIn, Twitter, and Facebook. The firm remains dedicated to ensuring that investor voices are not only heard but also upheld in the legal landscape.

For a comprehensive understanding of your rights and potential benefits, consider the insights provided by experts at Rosen Law Firm. Don’t miss out on this chance to reclaim what may be rightfully yours alongside fellow investors affected by PepGen's alleged wrongdoings.